Navigation Links
Sunesis in Medical Technology

SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases

SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... SAN FRANCISCO , Dec. 7 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today anno...erated. Conference Call Information sunesis management will host a conference call on Tuesday,...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

...NCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biophar...60 Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at www.sunesis.com . The webcast will be...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...SH," said Daniel Swisher, Chief Executive Officer, sunesis Pharmaceuticals. "Our goal is to advance voreloxin...been escalated to 75 mg/m2 dosed every four weeks. sunesis expects to complete enrollment of the 75 mg/m2 coh...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...n an acute need for new treatment options. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...or the treatment of solid and hematologic cancers. sunesis has built a highly experienced cancer drug develop...

Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)

... In conjunction with this strategic restructuring, sunesis expanded the company's late-stage development lead...tently well tolerated in multiple clinical trials. sunesis is currently conducting Phase 2 clinical trials of...nation with cytarabine for the treatment of AML. sunesis continues ongoing trials in its earlier-stage clin...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

...ofile demonstrated in this Phase 2 clinical trial, sunesis increased the dose of voreloxin in this trial to 6...een observed. Based on voreloxin's safety profile, sunesis recently announced that the protocol for the ongoi...25 percent to 75 mg/m(2) given once every 28 days. sunesis expects to enroll approximately 30 patients at thi...

Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress

...will be available following each conference on the sunesis corporate website at http://www.sunesis.com . About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...al in patients with advanced solid tumors. About sunesis Pharmaceuticals ...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...a from this trial indicate clear clinical benefit, sunesis could initiate a pivotal trial in this highly unde...medical conference toward the end of this year." sunesis previously reported promising results from its Pha...lerated weekly dose of 72 mg/m2 was established. sunesis also announced today that voreloxin has been accep...

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

...by the MMRC Validation Team, in collaboration with sunesis scientists, of SNS-032 in human myeloma cell lines...cell lymphoma cell lines" (Abstract #756). About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research

...ch (AACR) being held April 12-16 in San Diego, CA. sunesis has built a portfolio of product candidates in onc...ibit Hall B-F, San Diego Convention Center About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

...ar survival rates at less than 30 percent. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...rapeutics for oncology and other serious diseases. sunesis has built a broad product candidate portfolio thro...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... Center in Atlanta, Georgia. On December 10, 2007, sunesis management will host a conference call for investo... a.m. to 7:00 p.m. Conference Call Information sunesis management will host a conference call to discuss ...ors and Media - Calendar of Events" section of the sunesis website at http://www.sunesis.com . Please log on...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

...- /ADVANCE FOR RELEASE AT 3:30 P.M. EDT, TODAY/ -- sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical...nt progressed within 60 days of initial response. sunesis plans to enroll approximately 55 patients in this ...hirty-one patients have been enrolled to date, and sunesis expects to complete enrollment and present additio...

Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

...ug-resistant models. About SNS-314 Discovered by sunesis using the company's discovery platform, SNS-314 is...le in the abnormal proliferation of tumors. About sunesis Pharmaceuticals sunesis is a clinical-stage biopharmaceutical company focu...

Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility

..., Calif., March 20, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. , presented non-clinical dat...er Therapies (TAT 2007) meeting held in Amsterdam, sunesis researchers presented results showing SNS-314's an...of this year. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...

Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research

..., Calif., April 13, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com... 7, board #1. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

...l lymphoma. Non-clinical studies were conducted by sunesis evaluating SNS-032's mechanism of action and in vi...ce apoptosis. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association

...O, Calif., June 01, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that the com...session. About Sunesis' Oncology Programs sunesis has built a rich portfolio of product candidates i...hibition of the cell-cycle and survival signaling. sunesis is currently conducting Phase 2 clinical trials in...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...O, Calif., June 11, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. presented positive data from...odels while sparing normal hematopoietic recovery. sunesis plans to initiate a Phase 1b clinical trial of SNS...NS-032 to Flavopirodol In a second presentation, sunesis reported the results of studies evaluating its cyc...

Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference

...O, Calif., July 03, 2007 /PRNewswire-FirstCall/ -- sunesis Pharmaceuticals, Inc. today announced that Eric Bj...ss the webcast of the presentation by visiting the sunesis website at sunesis website for two weeks until July 26, 2007. Optio...
Other Tags
(Date:12/22/2014)... 22, 2014  The 2014 Holiday Season may be the ... Intelligence reports that the long anticipated floodgates for consumer ... demand for smart phones, tablets, and wearable mobile devices ... 2.5 billion users with nearly 4.8 billion biometric devices ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
(Date:12/17/2014)... is fundamentally transforming the travel experience and nowhere is ... past decade, ePassports, biometric readers, and secure document scanners ... control via eGates and Automated Passport Control (APC) Kiosks ... borders across the globe. According to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
Other Contents